Relmada Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Relmada Therapeutics generated cash of -$51,659,206, which is more than the previous year. Cash used in financing activities reached the amount of -$98,463 last year. Net change in cash is therefore -$1,304,337.
Cash Flow
| 2012 | -7.56K | 0 | 13.5K |
|---|---|---|---|
| 2013 | -11.85K | -1.8K | 20K |
| 2016 | -13.14M | -562.25K | -263.75K |
| 2018 | -6.00M | -12.39K | 6.54M |
| 2019 | -12.09K | -80.16K | 126.10K |
| 2020 | -27.80M | -34.44M | 28.47M |
| 2021 | -91.87M | -54.11M | 187.93M |
| 2022 | -103.80M | 19.73M | 45.02M |
| 2023 | -51.65M | 50.45M | -98.46K |
RLMD Cash Flow Statement (2012 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2015 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 5.39M | 44.44M | 2.49M | 36.27M | 2.23K | 1.71M | 22.46M | 8.94K | 3.01K |
Operating activities | |||||||||
Net income | -98.79M | -157.04M | -125.75M | -59.45M | -15.00K | -8.96M | -2.97M | -45.01K | -12.05K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 0 | 0 | 1.25K | 3.75K | 4 | 2.62K | 54.81K | 250 | 0 |
Stock-based compensation expense | 43.81M | 44.19M | 40.49M | 20.77M | 2.76K | 517.99K | 1.20M | 0 | 0 |
| Deferred income tax benefit | 43.81M | 44.19M | 40.49M | 20.77M | 2.76K | 517.99K | 1.20M | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 512.43K | -426.05K | 79.45K | 0 | 0 | 224.98K | -231 | 0 | 0 |
Inventories | 0 | 426.05K | -79.45K | 0 | 0 | 0 | 0 | 3.23K | 491 |
Accounts payable | -1.75M | 421.04K | 2.84M | 7.82M | 0 | 157.39K | 424.42K | 26.50K | 6.99K |
Cash generated by operating activities | -51.65M | -103.80M | -91.87M | -27.80M | -12.09K | -6.00M | -13.14M | -11.85K | -7.56K |
Investing activities | |||||||||
Purchases Of Investments | -90.46M | -47.29M | -222.98M | -182.05M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | -12.39K | -562.25K | -1.8K | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 50.45M | 19.73M | -54.11M | -34.44M | -80.16K | -12.39K | -562.25K | -1.8K | 0 |
Financing activities | |||||||||
Common Stock Issued | 0 | 42.72M | 185.31M | 20.52M | 0 | 0 | 0 | 20K | 13.5K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -110.24K | 0 | 6.54M | -263.75K | 0 | 0 |
Cash used in financing activities | -98.46K | 45.02M | 187.93M | 28.47M | 126.10K | 6.54M | -263.75K | 20K | 13.5K |
Net Change In Cash | -1.30M | -39.04M | 41.94M | -33.78M | 6.97K | 528.43K | -13.96M | 6.34K | 5.93K |
Cash at end of period | 4.09M | 5.39M | 44.44M | 2.49M | 9.21K | 2.23M | 8.50M | 15.29K | 8.94K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |